NYSE:ELAN - Elanco Animal Health Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $34.60
  • Forecasted Upside: 45.26 %
  • Number of Analysts: 6
  • Breakdown:
  • 0 Sell Ratings
  • 3 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
▲ +0.49 (2.10%)

This chart shows the closing price for ELAN by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Elanco Animal Health Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ELAN and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ELAN

Analyst Price Target is $34.60
▲ +45.26% Upside Potential
This price target is based on 6 analysts offering 12 month price targets for Elanco Animal Health in the last 3 months. The average price target is $34.60, with a high forecast of $0.00 and a low forecast of $0.00. The average price target represents a 45.26% upside from the last price of $23.82.

This chart shows the closing price for ELAN for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 6 investment analysts is to buy stock in Elanco Animal Health. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 6 buy ratings
  • 4 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 5 buy ratings
  • 4 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 7 buy ratings
  • 5 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 5 buy ratings
  • 5 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 5 buy ratings
  • 5 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 5 buy ratings
  • 4 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 5 buy ratings
  • 3 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 3 buy ratings
  • 3 hold ratings
  • 0 sell ratings

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 3 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/19/2022The Goldman Sachs GroupLower Price TargetBuy$37.00 ➝ $32.00Low
5/17/2022Morgan StanleyLower Price TargetOverweight$37.00Low
2/28/2022BarclaysBoost Price TargetEqual Weight$30.00 ➝ $32.00Low
12/8/2021BarclaysReiterated RatingNeutral ➝ HoldHigh
11/18/2021Morgan StanleyInitiated CoverageOverweight$40.00Medium
10/28/2021Stifel NicolausDowngradeBuy ➝ Hold$37.00 ➝ $34.00Medium
8/5/2021Credit Suisse GroupInitiated CoverageOutperform$38.00High
6/15/2021Cleveland ResearchUpgradeUnderperform ➝ NeutralMedium
5/17/2021CitigroupReiterated RatingBuy$39.00 ➝ $42.00High
5/11/2021G.ResearchUpgradeHold ➝ BuyLow
5/11/2021GabelliUpgradeHold ➝ BuyMedium
5/11/2021BarclaysUpgradeUnderweight ➝ Equal Weight$25.00 ➝ $29.00Medium
4/20/2021Stifel NicolausInitiated CoverageBuy$37.00N/A
4/14/2021Stifel NicolausInitiated CoverageBuy$37.00Low
3/29/2021GabelliReiterated RatingBuy ➝ Hold$32.00High
3/22/2021GabelliDowngradeBuy ➝ Hold$32.00High
3/22/2021Raymond JamesReiterated RatingHoldHigh
3/8/2021CitigroupBoost Price Target$35.00 ➝ $39.00Low
2/26/2021Credit Suisse GroupUpgradeNeutral ➝ Outperform$33.00 ➝ $38.00High
12/9/2020ArgusDowngradeBuy ➝ HoldMedium
11/23/2020Morgan StanleyBoost Price TargetOverweight$31.00 ➝ $41.00High
11/9/2020BarclaysDowngradeOverweight ➝ Underweight$35.00 ➝ $25.00High
10/26/2020BarclaysBoost Price TargetOverweight$25.00 ➝ $35.00Medium
10/7/2020Raymond JamesReiterated RatingHoldMedium
10/1/2020CitigroupBoost Price TargetBuy$27.00 ➝ $32.00Medium
9/28/2020Raymond JamesReiterated RatingHoldLow
8/20/2020Morgan StanleyUpgradeEqual Weight ➝ Overweight$24.00 ➝ $31.00High
8/18/2020ArgusBoost Price TargetPositive ➝ Buy$26.00 ➝ $30.00Low
8/12/2020Credit Suisse GroupInitiated CoverageNeutral$27.00Medium
8/4/2020The Goldman Sachs GroupInitiated CoverageBuy$26.50High
7/27/2020Cleveland ResearchDowngradeNeutral ➝ Underperform$19.00High
7/20/2020Bank of AmericaBoost Price TargetBuy$26.00 ➝ $28.00Low
5/15/2020CitigroupLower Price TargetBuy$35.00 ➝ $27.00Medium
5/13/2020BarclaysReiterated RatingBuy$25.00Medium
4/2/2020Morgan StanleyDowngradeOverweight ➝ Equal WeightHigh
3/25/2020Credit Suisse GroupReiterated RatingBuyHigh
1/14/2020GabelliReiterated RatingBuyHigh
1/9/2020Raymond JamesInitiated CoverageMarket PerformHigh
12/19/2019Bank of AmericaUpgradeNeutral ➝ Buy$34.00High
11/20/2019UBS GroupLower Price TargetNeutral$30.00 ➝ $28.00Low
11/7/2019Morgan StanleyUpgradeEqual ➝ Equal Weight$34.00 ➝ $32.00Medium
9/26/2019Cleveland ResearchReiterated RatingHoldLow
9/23/2019BarclaysInitiated CoverageOverweight$36.00Medium
9/9/2019The Goldman Sachs GroupInitiated CoveragePositiveMedium
8/26/2019Bank of AmericaDowngradeBuy ➝ Neutral$30.00Low
8/15/2019UBS GroupUpgradeSell ➝ Neutral$31.00 ➝ $30.00Medium
5/22/2019GuggenheimInitiated CoverageNeutral ➝ NeutralLow
5/10/2019BMO Capital MarketsBoost Price TargetMarket Perform$32.00 ➝ $35.00Low
3/20/2019UBS GroupInitiated CoverageSell$29.00 ➝ $28.00Low
3/18/2019Bank of AmericaUpgradeNeutral ➝ Buy$30.95Low
3/13/2019Morgan StanleyInitiated CoverageEqual ➝ Equal Weight$34.00Low
2/11/2019William BlairInitiated CoverageMkt Perform ➝ Market Perform$29.71Medium
1/23/2019UBS GroupInitiated CoverageSell ➝ Sell$29.00High
1/15/2019ArgusInitiated CoverageBuy$37.00Low
1/4/2019Credit Suisse GroupReiterated RatingHold$33.00Low
12/19/2018BMO Capital MarketsLower Price TargetMarket Perform$37.00 ➝ $32.00High
12/17/2018Credit Suisse GroupReiterated RatingHold$36.00High
11/13/2018BMO Capital MarketsBoost Price TargetMarket Perform ➝ Market Perform$33.00 ➝ $37.00Low
10/15/2018Credit Suisse GroupInitiated CoverageNeutral ➝ Neutral$36.00High
10/15/2018CitigroupInitiated CoverageBuy ➝ Buy$37.00High
10/15/2018CowenInitiated CoverageOutperformLow
10/15/2018Bank of AmericaInitiated CoverageNeutral ➝ Neutral$34.00Low
10/15/2018Morgan StanleyInitiated CoverageEqual ➝ Equal Weight$35.00Low
10/15/2018JPMorgan Chase & Co.Initiated CoverageOverweight ➝ Overweight$38.00Low
10/15/2018The Goldman Sachs GroupInitiated CoverageNeutral ➝ Neutral$30.00Low
10/12/2018Craig HallumInitiated CoverageHoldLow
9/26/2018BMO Capital MarketsInitiated CoverageMarket Perform$33.00High
9/19/2018GabelliInitiated CoverageBuy ➝ Buy$32.00N/A
(Data available from 5/26/2017 forward)

News Sentiment Rating

0.24 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 4 very positive mentions
  • 6 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
  • 1 very positive mentions
  • 10 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
  • 3 very positive mentions
  • 8 positive mentions
  • 3 negative mentions
  • 2 very negative mentions
  • 0 very positive mentions
  • 9 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
  • 4 very positive mentions
  • 11 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
  • 2 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
  • 3 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
  • 5 very positive mentions
  • 22 positive mentions
  • 4 negative mentions
  • 0 very negative mentions

Current Sentiment

  • 5 very positive mentions
  • 22 positive mentions
  • 4 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.
Elanco Animal Health logo
Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands. The company sells its products to third-party distributors; veterinarians; and farm animal producers, including beef and dairy farmers, as well as pork, poultry, and aquaculture operations. Elanco Animal Health Incorporated was founded in 1954 and is headquartered in Greenfield, Indiana.
Read More

Today's Range

Now: $23.82
Low: $23.62
High: $23.98

50 Day Range

MA: $25.28
Low: $20.82
High: $27.53

52 Week Range

Now: $23.82
Low: $20.51
High: $37.49


134,926 shs

Average Volume

4,748,063 shs

Market Capitalization

$11.29 billion

P/E Ratio


Dividend Yield




Frequently Asked Questions

What sell-side analysts currently cover shares of Elanco Animal Health?

The following sell-side analysts have issued research reports on Elanco Animal Health in the last twelve months: Barclays PLC, Cleveland Research, Credit Suisse Group AG, Morgan Stanley, Stifel Nicolaus, The Goldman Sachs Group, Inc., and Zacks Investment Research.
View the latest analyst ratings for ELAN.

What is the current price target for Elanco Animal Health?

0 Wall Street analysts have set twelve-month price targets for Elanco Animal Health in the last year. Their average twelve-month price target is $34.60, suggesting a possible upside of 48.3%.
View the latest price targets for ELAN.

What is the current consensus analyst rating for Elanco Animal Health?

Elanco Animal Health currently has 3 hold ratings and 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe ELAN will outperform the market and that investors should add to their positions of Elanco Animal Health.
View the latest ratings for ELAN.

How do I contact Elanco Animal Health's investor relations team?

Elanco Animal Health's physical mailing address is 2500 INNOVATION WAY, GREENFIELD IN, 46140. The company's listed phone number is (877) 352-6261 and its investor relations email address is [email protected] The official website for Elanco Animal Health is www.elanco.com. Learn More about contacing Elanco Animal Health investor relations.